There are controversies in the nomenclature and classification of necrotizing renal vasculitis, since the concept of
antineutrophil cytoplasmic antibody (ANCA)-related vasculitis was introduced following the discovery of ANCAin 1982 (1) (2) (3) (4) . The case report of Satoh et al which appears in this issue of Internal Medicine (5) Renal limited vasculitis and pi-Cres.GN: There are some reports that pi-Cres.GN represents a form of renal limited vasculitis before and after the concept of MPAor ANCA-related vasculitis was widely circulated (4, (9) (10) (11) (12) (13) (14) (15) . Weexamined the organ involvement in 53 patients with pi-Cres.GN associated with MPO-ANCA. They were classified into 3 groups; Cres.GN only -15 cases (28%), Cres.GN with pulmonary hemorrhage -21 cases (40%), Cres.GN, pulmonary hemorrhage, and systemic vasculitis -17 cases (32%) (16). This data suggests that it is reasonable to regard pi-Cres.GN as a renal limited vasculitis as the opinion of Satoh et al (5).
Relapse ofvasculitis: There is controversy as to the relapse rate of classical PN (5, 7, 17) . Some insist there is no relapse, and others insist there is a high relapse. On the contrary, the relapse of MPAis between 15-30% in many reports, although the interval between the initial attack and second attack is variable as reviewed by Satoh et al (5) . The clinical importance is that most of the relapse occurred, whenmaintained immunosuppressive therapy was stopped as in the case of Satoh et al. A short duration of therapy might induce a high rate of relapse, whereas long-term intensive therapy might lead to the association of serious complications related to drug toxicity. Whether the rising ANCAtiter predicts the relapse of MPAor not is still a matter of debate (1, 4, (18) (19) (20) , although our experience indicates that the rise ofANCA titer maybe an excellent marker for the intensification of immunosuppressive therapy to prevent relapse (6) . In most of the cases with MPA,serial quantitative assay of ANCA is needed to avoid relapse and to reduce drug toxicity of immunosuppressive treatment.
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